Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

Experts say there’s no evidence GLP-1s can be absorbed through the skin — and these patches don’t contain the FDA-approved ...

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other ...

New research from experts at the University of Virginia (UVA) says that GLP-1 drugs may help people lose weight, but do not ...

Explore how semaglutide and tirzepatide may protect against dementia and stroke—keep reading for clinical implications and evidence.

For patients with type 2 diabetes, GLP-1 RAs are associated with an increased risk for GERD compared with SGLT-2 inhibitors.

Patients with idiopathic intracranial hypertension who use a GLP-1 receptor agonist are less likely to experience symptoms, require medications, or undergo surgery.

Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...

Q: I’m trying to improve my nutrition, but it’s not easy. Can you help me feel more motivated, please? — Jenny T., Evanston, Ill.

A study reveals potentially fatal side effects of GLP-1 drugs, that people are using to lose weight. It’s well known that ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.